Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RYR2 | Q92736 | 2/20 | 0.31 |
| ▸ | INMT | O95050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5759488 | 0.75 | GAA (0.55) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL5758572 | 0.75 | GAA (0.55) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL13089134 | 0.72 | MEN1 (0.43) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL30480839 | 0.72 | MEN1 (0.43) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL5758250 | 0.70 | KDM4E (0.31) | MEN1GAAKMT2A | |
| SCHEMBL5759829 | 0.69 | MEN1 (0.36) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL5760046 | 0.69 | MEN1 (0.36) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL88911 | 0.67 | GAA (0.96) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL3556450 | 0.67 | GAA (0.96) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL29364653 | 0.67 | GAA (0.96) | MEN1ALDH1A1GAAKMT2ARYR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101869-B2 | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER INC. (US) | 2006-09-05 | — | — | US | claimed |
| EP-1242403-B1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PROD INC (US) | 2006-01-04 | — | — | EP | claimed |
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | BLUMENKOPF TODD A (US) | 2003-10-09 | — | — | US | claimed |
| CN-1402720-A | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER PROD INC (US) | 2003-03-12 | — | — | CN | claimed |
| US-7101869-B2 | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1242403-B1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PROD INC (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | BLUMENKOPF TODD A (US) | 2003-10-09 | — | — | US | disclosed |
| CN-1402720-A | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER PROD INC (US) | 2003-03-12 | — | — | CN | disclosed |
| EP-1242403-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | Pfizer Products Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001040215-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | CCR1, AOC1, NOD1 | MEN1 3785/4885ALDH1A1 495/4885GAA 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.